Short answer
NEOGEN CORP (NEOG) filed its Q3 2026 10-Q quarterly report on Oct 7, 2026 for the quarter ended Aug 31, 2026. Quarterly revenue was $223M (up 6.5% year over year) with net income of −$12M.
Q3 2026 key financials · XBRL
- Revenue
- $223M
- +6.5% YoY
- Net income
- −$12M
- −132.7% YoY
- Operating margin
- -0.8%
- Gross margin
- 47.4%
- EPS (diluted)
- −$0.05
- −129.4% YoY
Source: XBRL data from the NEOGEN CORP (NEOG) Q3 2026 10-Q on SEC EDGAR. USD.
NEOGEN CORP Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $222.8M, up $13.6M or 6.5% YoY
- Gross margin 47.4% vs 45.4% YoY, operating loss $(1.8)M vs $(16.1)M
- Food Safety strongest segment: revenue $163.2M, up 7.3%; Animal Safety revenue $59.6M, up 4.4%
- Cash $172.0M; operating cash flow $12.9M vs $10.8M, with $20.0M term-loan prepayment
- Headwinds: inflation, tariffs, elevated interest rates, geopolitical tensions; Genomics divestiture reviews expected through December 2026
Risk Factors
- Genomics divestiture risk: ACCC and NZCC moved reviews to phase two, potentially delaying the $160.0 million Zoetis transaction
- Product compliance risk: FDA Warning Letter followed contamination findings involving recalled Vet HyCoat units
- Litigation risk: securities class-action dismissal appealed on September 8, 2026, leaving appeal exposure unresolved
- Operational risk: Petrifilm internal manufacturing preparation creating duplicative costs and production inefficiencies
- Debt liquidity risk: $774.2 million net debt outstanding, with $199.9 million revolving borrowing capacity available
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other NEOGEN CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.